Laurus Labs Q2 Profit Jumps 126% to ₹441 Crore; EBITDA Rises 78%

Mumbai, October 30: Laurus Labs Limited shares were trading at ₹2,354.60, up 4.93%, at 11:07:58 AM IST on Friday. Separately, the pharmaceutical company reported a 126% year-on-year increase in consolidated net profit attributable to equity holders to ₹441.48 crore for Q2 FY27, while revenue from operations rose 33% to ₹2,206.37 crore.

Laurus Labs Q2 FY27 Financial Results

Consolidated EBITDA increased 78% to ₹762 crore from ₹429 crore in the year-ago quarter. The EBITDA margin expanded to 34.5% from 26%, an improvement of 850 basis points. Profit before tax rose 119% to ₹592 crore from ₹270 crore.

Gross margin improved to 63% from 59.9%, supported by a favourable business mix and improved capacity efficiency.

For the first half of FY27, revenue grew 31% to ₹4,233 crore, while EBITDA increased 72% to ₹1,406 crore. Net profit attributable to equity holders rose 126% to ₹809 crore.

CDMO Business Leads Revenue Growth

Laurus Labs’ contract development and manufacturing organisation (CDMO) revenue increased 75% year-on-year to ₹904 crore in Q2 FY27. Small-molecule CDMO revenue rose 86% to ₹875 crore.

The Affordable Medicines division reported revenue of ₹1,302 crore, up 15%. Meanwhile, revenue from the Bio division declined 38% to ₹29 crore.

The company also operationalised its first commercial-scale peptide manufacturing facility in Visakhapatnam and continued capacity expansion to address demand.

Acquisitions and Interim Dividend

Laurus Labs signed an agreement to acquire a 60% stake in Canada’s Galenvs Sciences, which specialises in oligonucleotide technologies and precision magnetic nanoparticles. The proposed investment is USD 3.75 million, including a primary infusion of USD 2.75 million, subject to due diligence.

The company also agreed to acquire a 52% stake in SI&C Resins to strengthen its peptide-resin technology and supply chain. Additionally, it declared an interim dividend of ₹1 per share.

Laurus Labs Share Price Performance

The Laurus Labs share price was trading at ₹2,354.60, up 4.93% on Friday, October 30, compared with the previous close of ₹2,244.00. The stock opened at ₹2,246.60.

The quote reflects the intraday price displayed at 11:07:58 AM IST. The price movement alone does not establish a direct link between the financial results and the stock’s performance.

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company operating across active pharmaceutical ingredients, finished dosage forms, CDMO services and biotechnology.

Conclusion

Laurus Labs reported higher revenue, EBITDA and profit in Q2 FY27, with CDMO and Affordable Medicines contributing to growth. Its planned investments in Galenvs Sciences and SI&C Resins are aimed at expanding its capabilities in oligonucleotides and peptide manufacturing.

Source:

• https://www.nseindia.com/get-quote/equity/LAURUSLABS/Laurus-Labs-Limited
• https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026153754_1PressRelease29102026.pdf